Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 19/20 | 0.51 |
| ▸ | PIK3CD | O00329 | 15/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 14/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 13/20 | 0.46 |
| ▸ | PIK3R1 | P27986 | 11/20 | 0.46 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.44 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | PRKDC | P78527 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL734503 | 0.95 | PIK3CG (0.49) | PIK3CGPIK3CDPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL733966 | 0.93 | PIK3CD (0.49) | PIK3CGPIK3CDPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL733237 | 0.90 | PIK3CG (0.51) | PIK3CGPIK3CDPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL733233 | 0.88 | PIK3CD (0.47) | PIK3CGPIK3CDPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL735272 | 0.87 | PIK3CD (0.45) | PIK3CGPIK3CDPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL735037 | 0.86 | PIK3CG (0.47) | PIK3CGPIK3CDPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL734484 | 0.86 | PIK3CG (0.37) | PIK3CGPIK3CDPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL733512 | 0.85 | PIK3CG (0.51) | PIK3CGPIK3CDPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL732376 | 0.85 | PIK3CD (0.47) | PIK3CGPIK3CDPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL732766 | 0.85 | PIK3CD (0.52) | PIK3CGPIK3CDPIK3CBPIK3CAPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140154772-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2014-06-05 | — | — | US | claimed |
| EP-1278748-B1 | INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA | ICOS CORP (US) | 2011-03-23 | — | — | EP | claimed |
| JP-4642309-B2 | — | — | 2011-03-02 | — | — | JP | claimed |
| EP-1885356-A2 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS FOR INHIBITING LEUKOCYTE ACCUMULATION | ICOS CORPORATION (US) | 2008-02-13 | — | — | EP | claimed |
| EP-1755609-A1 | METHODS FOR TREATING AND/OR PREVENTING ABERRANT PROLIFERATION OF HEMATOPOIETIC CELLS | ICOS CORPORATION (US) | 2007-02-28 | — | — | EP | claimed |
| EP-1750715-A1 | METHODS FOR TREATING MAST CELL DISORDERS | ICOS CORPORATION (US) | 2007-02-14 | — | — | EP | claimed |
| EP-1750714-A1 | PHOSPHOINOSITIDE 3-KINASE DELTA SELECTIVE INHIBITORS FOR INHIBITING ANGIOGENESIS | VANDERBILT UNIVERSITY (US) | 2007-02-14 | — | — | EP | claimed |
| WO-2006089106-A2 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS FOR INHIBITING LEUKOCYTE ACCUMULATION | ICOS CORPORATION (US) | 2006-08-24 | — | — | WO | claimed |
| US-20060106038-A1 | Methods for treating and/or preventing aberrant proliferation of hematopoietic cells | ICOS CORPORATION (US) | 2006-05-18 | — | — | US | claimed |
| US-20060079538-A1 | Methods for inhibiting angiogenesis | VANDERBILT UNIVERSITY | 2006-04-13 | — | — | US | claimed |
| US-20050043239-A1 | Methods of inhibiting immune responses stimulated by an endogenous factor | ICOS CORPORATION | 2005-02-24 | — | — | US | claimed |
| WO-2005016348-A1 | METHOD OF INHIBITING IMMUNE RESPONSES STIMULATED BY AN ENDOGENOUS FACTOR | ICOS CORPORATION (US) | 2005-02-24 | — | — | WO | claimed |
| US-20040266780-A1 | for example, 2-(6-aminopurin-9-ylmethyl)-3-(2-chlorophenyl)-6,7-dimethoxy-3H-quinazolin-4-one | ICOS CORPORATION | 2004-12-30 | — | — | US | claimed |
| US-6800620-B2 | CONTACTING LEUKOCYTES, OSTEOCLASTS WITH AN ENZYME INHIBITORS, A 9H-PURIN-3H-QUINAZOLIN-4-ONE DERIVATIVES, TREATING BONE-RESORPTION DISORDER, ANTIPROLIFERATIVE AGENTS TREATING LEUKEMIA CELLS | ICOS | 2004-10-05 | — | — | US | claimed |
| JP-2003531209-A | — | — | 2003-10-21 | — | — | JP | claimed |
| US-20030195211-A1 | Inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION | 2003-10-16 | — | — | US | claimed |
| US-6518277-B1 | Disrupting leukocyte function | ICOS CORPORATION | 2003-02-11 | — | — | US | claimed |
| EP-1278748-A2 | INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2003-01-29 | — | — | EP | claimed |
| US-20020161014-A1 | Purinyl substituted quinazoline-4-one derivatives | ICOS CORPORATION, A DELAWARE CORPORATION | 2002-10-31 | — | — | US | claimed |
| WO-2001081346-A2 | INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2001-11-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140154772-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PIK3CG | PIK3CG 3/4885PIK3CD 1/4885PIK3CB 4/4885 |
| US-20020161014-A1 | Purinyl substituted quinazoline-4-one derivatives | PIK3CD, PIK3CA, PIK3CG | PIK3CG 3/4885PIK3CD 1/4885PIK3CB 5/4885 |
| US-20060079538-A1 | Methods for inhibiting angiogenesis | FLT4, KDR, PDGFRB | PIK3CG 13/4885PIK3CD 6/4885PIK3CB 14/4885 |
| US-20040266780-A1 | for example, 2-(6-aminopurin-9-ylmethyl)-3-(2-chlorophenyl)-6,7-dimethoxy-3H-quinazolin-4-one | PIK3CD, PIK3CA, PIK3CG | PIK3CG 3/4885PIK3CD 1/4885PIK3CB 4/4885 |
| US-20050043239-A1 | Methods of inhibiting immune responses stimulated by an endogenous factor | PI4KB, PI4KA, PIK3CD | PIK3CG 10/4885PIK3CD 3/4885PIK3CB 6/4885 |
| US-20060106038-A1 | Methods for treating and/or preventing aberrant proliferation of hematopoietic cells | MCL1, NFATC1, MKI67 | PIK3CG 57/4885PIK3CD 25/4885PIK3CB 37/4885 |
| US-20030195211-A1 | Inhibitors of human phosphatidylinositol 3-kinase delta | PIK3CD, PIK3CA, PIK3CG | PIK3CG 3/4885PIK3CD 1/4885PIK3CB 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.